PDUFA meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA to hear stakeholder testimony Dec. 7 in Bethesda, Md., on what aspects of user fee program should be retained or changed and whether program should allow use of user fee funding to monitor post-approval drug safety. Agency also seeks input on how it can ensure PDUFA goals are met in wake of continued funding shortfalls and whether there should be flexibility in setting user fees to cover increased program costs. PDUFA legislative authority sunsets in September 2002; FDA held a similar public meeting last year (1"The Tan Sheet" Sept. 25, 2000, p. 8)...
You may also be interested in...
GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform
Generic drug user fees should be considered only in the context of changes to Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA at a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.